Skip to main content

NEOGENOMICS INC

For the period ended Dec 31, 2025. Filed Apr 6, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Dec 31, 2025 · Filed Apr 6, 2026

NEO$16.84+2.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:
☐Preliminary Proxy Statement
☐Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive Additional Materials
☐Soliciting Material under Rule 14a-12

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒No fee required.
☐Fee paid previously with preliminary materials.
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

April 6, 2026

9490 NeoGenomics Way

Fort Myers, Florida 33912

Fellow Stockholders,

On behalf of the Board of Directors, it is my pleasure to invite you to attend our 2026 Annual Meeting of Stockholders of NeoGenomics, Inc., which will be held on Thursday, May 21, 2026, at 10:00 a.m., Eastern Time (the "2026 Annual Meeting"). The 2026 Annual Meeting will be a completely virtual meeting conducted via live webcast.

Details regarding the 2026 Annual Meeting and the business to be conducted are described in the accompanying Proxy Statement.

We are pleased to inform you that instead of a paper or electronic copy of our proxy materials, most of our stockholders will be mailed a Notice of Internet Availability of Proxy Materials (“Notice of Internet Availability”) on or about April 6, 2026. The Notice of Internet Availability contains instructions on how to access the proxy materials and how to submit your proxy over the Internet or by telephone. The Notice of Internet Availability also contains instructions on how to request a paper copy of our proxy materials, if desired. All stockholders who do not receive a Notice of Internet Availability, or who have not consented to receive their proxy materials electronically by email, will be mailed a paper copy of the proxy materials. Furnishing proxy materials over the Internet allows us to provide our stockholders with the information they need in a timely manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials.

Your vote is important to us. Please act as soon as possible to vote your shares. It is important that your shares be represented at the 2026 Annual Meeting, whether or not you plan to attend the live webcast of the 2026 Annual Meeting. Please vote electronically over the Internet, by telephone, or, if you receive a paper copy of the proxy card by mail, by returning your signed proxy card in the envelope provided. You may also vote your shares online during the 2026 Annual Meeting. Instructions on how to vote while participating at the 2026 Annual Meeting live via the Internet are posted at www.virtualshareholdermeeting.com/NEO2026.

On behalf of the Board of Directors and management, we thank you for your continued support and confidence in NeoGenomics, Inc.

Sincerely,

Lynn Tetrault

Non-Executive Chair of the Board of Directors

NOTICE OF 2026 ANNUAL MEETING OF STOCKHOLDERS

NOTICE IS HEREBY GIVEN that the 2026 Annual Meeting of Stockholders of NeoGenomics, Inc. (the "2026 Annual Meeting") will be held on Thursday, May 21, 2026, at 10:00 a.m., Eastern Time. The 2026 Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the 2026 Annual Meeting online and submit your questions during the 2026 Annual Meeting by visiting www.virtualshareholdermeeting.com/NEO2026. For instructions on how to attend and vote your shares at the 2026 Annual Meeting, see the information in the accompanying Proxy Statement.

Items of Business:

  1. To elect nine directors from the nominees named in the attached Proxy Statement.

  2. To approve, on a non-binding advisory basis, the compensation paid to the named executive officers.

  3. To approve the Second Amendment of the NeoGenomics, Inc. 2023 Equity Incentive Plan.

  4. To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

  5. To consider any other business properly brought before the 2026 Annual Meeting.

Record Date:

You can vote if you were a stockholder of record as of the close of business on March 23, 2026.

Proxy Voting:

By MailBy PhoneBy Internet

It is important that your shares be represented at the 2026 Annual Meeting regardless of the number of shares you hold. Whether or not you expect to virtually attend, please complete, date, sign and return the accompanying proxy card in the enclosed envelope or use the telephone or Internet methods of voting described on your proxy card to ensure the presence of a quorum at the meeting. Even if you have voted by proxy and you virtually attend the meeting, you may, if you prefer, revoke your proxy and vote your shares virtually during the 2026 Annual Meeting.

By Order of the Board of Directors

Alicia Olivo

EVP, General Counsel & Business Development

Important notice regarding the availability of proxy materials for the 2026 Annual Meeting of Stockholders to be held on Thursday, May 21, 2026. Our 2026 Proxy Statement and 2025 Annual Report to Stockholders are available at www.proxyvote.com.

TABLE OF CONTENTS

PROXY OVERVIEW1
CORPORATE GOVERNANCE2
Information Regarding Meetings and Committees of the Board8
PROPOSAL 1—ELECTION OF DIRECTORS11
Information as to Nominees and Other Directors11
Vote Required for Approval18
Board Recommendation18
PROPOSAL 2—ADVISORY VOTE ON EXECUTIVE COMPENSATION19
Vote Required for Approval19
Board Recommendation19
PROPOSAL 3—SECOND AMENDMENT OF THE 2023 EQUITY INCENTIVE PLAN20
Description of the Plan20
Vote Required for Approval24
Board Recommendation24
PROPOSAL 4—RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM25
Independent Registered Public Accounting Firm Fees25
Audit and Finance Committee Report26
Vote Required for Approval26
Board Recommendation26
EXECUTIVE OFFICERS27
COMPENSATION OF INDEPENDENT DIRECTORS29
EXECUTIVE COMPENSATION32
Compensation Discussion and Analysis32
Culture and Compensation Committee Report51
Executive Compensation Tables52
Summary Compensation Table52
Grants of Plan-Based Awards54
Narrative Disclosure to the Summary Compensation Table and the Grants of Plan Awards Table55
Options Exercised and Stock Vested58
Outstanding Equity Awards on December 31, 202556
Employment Agreements and Potential Payments Upon Termination or Change in Control58
Chief Executive Officer Pay Ratio61
Pay Versus Performance and Supporting Narrative62
Equity Compensation Plan Information65
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT66
FUTURE STOCKHOLDER PROPOSALS68
TRANSACTIONS WITH RELATED PERSONS69
OTHER MATTERS70
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 21, 202671
QUESTIONS AND ANSWERS ABOUT THE 2026 ANNUAL MEETING72
ANNEX A: SECOND AMENDMENT OF THE NEOGENOMICS, INC. 2023 EQUITY INCENTIVE PLANA-1
ANNEX B: NEOGENOMICS, INC. Reconciliation of Non-GAAP InformationB-1

Index of Frequently Requested Information

Auditor Fees25
Board Leadership Structure4
CEO Pay Ratio61
Clawback Policy20
Compensation Design36
Culture and Compensation Governance38
Director Attendance8
Director Independence5
Director Qualifications11
Managing Compensation Related Risks49
Nominee Biographies11
Pay Versus Performance62
Risk Oversight5
Stockholder Engagement40
Summary Compensation Table52
Use of an Independent Advisor39
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.